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Abstract 
 Human immune system is powerful and it has evolved over the past thousands 
of years to protect us from various foreign pathogens. In fact, very few pathogens can 
threaten a man with a competent immune system. The notorious Human 
Immunodeficiency Virus may be among those very few pathogens as it attacks human 
immune system; however, it does not mean men are left utterly weaponless in the face 
of HIV infection. The adaptive arm of the human immune system has historically 
received more attention, given that most vaccines to viral pathogens are based on this 
type of immune response. In the context of HIV infection, however, attempts to 
induce antibody responses or cell-mediated immunity with vaccine have yielded little 
success. As a result, research resource has shifted to look at the first-line protection 
that precedes the adaptive immunity. Restriction factors are among this innate arm of 
the immune system. Since 2002, many restriction factors have been described, many 
in the context of their antiretroviral activities. In this thesis essay, I attempted to cover 
some of the best-studied HIV restriction factors to date, including their potential 
antiviral mechanisms and how virus has developed ways to circumvent their 
inhibition effects. Many restriction factors are now on the verge of being translated 
into clinical products, so I tried to include some of the latest translational applications 
of restriction factors in this article. A common theme for most restriction factors is a 
constant “arm race” between the virus and the host, and therefore, in the end, I have 
included a short discussion on how, in a human perspective, men managed to stay on 
the battlefield with the ever-mutating HIV virus.  
Primary Reader: Richard Markham, M.D. 
Secondary Reader: Gary Ketner, Ph.D., Xiao-Fang Yu, M.D., D.Sc.  
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I. Introduction 
 Acquired Immune Deficiency Syndrome (AIDS) was first described as a new 
disease in 1981 among a group of young homosexual men. Those young individuals 
became sick and would soon die of either opportunistic infections or rare 
malignancies not commonly seen in immune competent people1. The etiological agent 
of AIDS was successfully isolated in 19852  and the virus was named Human 
Immunodeficiency Virus (HIV) shortly after3.  
In the following three decades, the AIDS pandemic has caused more fatalities 
than any other epidemic in human history. Since the start of the AIDS pandemic, 
approximately 75 million people have become infected with HIV globally and by 
2012, AIDS-related illnesses have claimed over 36 million lives4. HIV/AIDS is also 
predominantly a disease of the poor, disproportionately affecting the world’s “bottom 
billion”. Currently seventy percent of the people chronically infected with the HIV 
virus call the Sub-Saharan Africa region home, where a majority of new HIV 
infection cases take place each year4.  
Despite of the extensive damage HIV/AIDS has done, our understanding of 
HIV has come a long way during the past three decades. HIV is among the most well 
studied viruses within the scientific community and we now have a relatively clear 
picture of HIV’s viral life cycle. The most direct and tangible results from our study 
of the HIV virus are the discovery of a variety of antiretroviral drugs, targeting an 
array of viral life stages. The development of Highly Active Antiretroviral Therapy 
(HAART)5 6, employing simultaneous use of multiple antiretroviral agents, can 
effectively suppress viral replication and minimize the chance of viral drug resistance.  
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HIV infection has, for individuals who can afford these medications, become a 
chronic condition resembling asthma and diabetes.   
However, HAART does not eradicate HIV virus from one’s body and 
therefore does not provide a cure. With our current knowledge of the HIV latency7 
and the recent failures of HIV vaccine trials8 9, it becomes obvious that more basic 
research needs to be done to help us understand how the virus interacts with the host 
immune system during infection. Much research effort has been focusing on two 
levels of viral-host interaction—broadly defined innate immunity at the cellular level 
involving various restriction factors10 and adaptive immunity at the organism level 
involving broadly neutralizing antibodies11. In this essay, I am going to review the 
recent findings on host restriction factors and corresponding viral evasion 
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II. Restriction Factors 
 Mammalian cells express “a number of diverse, dominantly acting proteins 
that are widely expressed and function in a cell-autonomous manner to suppress virus 
replication” 10, These restriction factors, as they have been termed, act as the first line 
of defense against viral infection at the cellular level, as virus gains entry into the host 
cell and starts replication, and are thus considered part of innate immunity. Following 
the discovery of the first restriction factor in 200213, more than 30 different anti-HIV-
1 host restriction factors have been described12. Some of the best-characterized HIV 
restriction factors include apolipoprotein B mRNA-editing, enzyme-catalytic, 
polypeptide-like 3G (APOBEC3G)13, Tetherin (also known as BST-2)14, Tripartite 
motif-containing Motif 5 α  (TRIM5α)15 and Sterile Alpha Motif Histidine-Aspartic 
(HD) domain-containing protein 1 (SAMHD1)16.  
Although restriction factors target different steps of the viral life cycle, there 
are many shared features among them. They share the capacity to display potent 
antiviral function as a single gene and in general, they are germline-encoded, IFN-
inducble, yet expressed constitutively at low level10. Although the majority of 
restriction factors discovered to date are retrovirus-specific, it is likely a reflection of 
the lack of research resources on other viruses. Many restrictions factors, such as 
MxA, which is active against a variety of viruses including Influenza109 and PKR 
against poxvirus17, have been described. Similar experimental approaches have been 
used to identify most of the restriction factors. For example, APOBEC3G, tetherin 
and the most recently discovered Mx2 were identified using comparative 
transcriptomics, which allows high throughput screening of genes that are 
preferentially expressed in restrictive cells compared to susceptible cells. Those genes 
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can later be validated if the ectopically expressed gene can transform susceptible cells 
into restrictive cells13 14 18. As in the case of TRIM5α, a more direct screening 
approach was utilized. A cDNA library derived from the restrictive cells were first 
created and expressed in the susceptible cells, followed by a selection for cells that 
acquire viral resistance phenotypes15. In contrast, SAMHD1 was uncovered by over-
expressing a viral protein Vpx (only in HIV-2 and SIV) in restrictive cell lines and 
subsequently looking for a host protein that interacts with Vpx with Mass 
spectrometry19 or a proteomic screen16.  
Unfortunately, the virus has also come up with mechanisms for counteracting 
the pressure imposed by restriction factors. In most cases, the viral evasion 
mechanisms are tied to viral accessory proteins—a group of proteins that play limited 
roles in HIV infection in vitro (in permissive cell lines) yet are absolutely essential for 
in vivo infection. Some viral accessory proteins, such as Vif and Vpx, are able to 
antagonize host restriction factors by simultaneously binding to the restriction factors 
and recruiting a cellular ubiquitin ligase complex, which results in the ubiquitylation 
and eventual proteasomal degradation of the restriction factors.   
In the next five sections, I will review the four best-characterized restriction 
factors and the corresponding viral evasion mechanisms, as well as some other 
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III. APOBEC3G and Vif 
 APOBEC3 family proteins, and most notably APOBEC3G, were the first 
discovered group of HIV restriction factors. Initially, the Malim group, among other 
research teams, found that the HIV accessory protein Vif is required for HIV 
replication in primary cell types, such as CD4+ cells, while a Vif-defective HIV strain 
is still able to effectively replicate in certain permissive cell lines, such as 293T 
cells20. It was strongly suspected that a certain host factor(s) was involved in 
determining the permissiveness of the host cells; however, the nature of this factor 
was not clear—either a host restriction factor could be limiting viral replication in 
nonpermissive cells or a host cofactor, present in permissive cells, facilitated viral 
replication.  
 
Figure 1. Cell fusion experiment can differentiate between a host restrictive inhibitor 
and a host cofactor that helps viral replication. Permissive/non-permissive phenotypes 
can be caused either by the absence/presence of a restriction factor or by the 
presence/absence of a host cofactor. After the cell fusion, if the permissiveness 
phenotype is associated with a restriction factor, the fused cell will get this restriction 
factor from the non-permissive cells, and thus become non-permissive. In contrast, if 
the permissiveness phenotype is associated with a host cofactor, the fused cell will 
inherit the cofactor from permissive cells and thus allowing the virus to replicate. 
Adapted from Malim and Bieniasz. Cold Spring Harb. Perspect. Med. 2012. 
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Subsequently, the Malim group preformed a brilliant series of cell fusion experiments 
(Figure 1) that confirmed that the permissiveness phenotype is due to a host 
restriction factor19. Not long after that, the same group identified a cellular gene 
CEM1513. The expression of CEM15 creates the non-permissiveness phenotype in 
293T cells when infected with Vif-defective virus, but the antiviral effect CEM15 
confers is overcome by the presence of Vif. A database search of the CEM15 gene 
later showed significant similarities between CEM15 and the cytidine deaminase 
APOBEC1. As a result, CEM15 was named APOBEC3G later and the fact that it 
belongs to the APOBEC family also shed some light on the potential antiviral 
mechanism of APOBEC3G. With the successful identifications of host restriction 
factor APOBEC3G and its corresponding viral antagonist Vif, two major questions 
remain to be solved—how does APOBEC3G inhibit Vif-defective HIV replication 
and how does Vif antagonize APOBEC3G.  
 As mentioned previously, APOBEC3G belongs to the APOBEC family of 
proteins, which consists of 11 members in humans21. The first uncovered APOBEC 
protein, APOBEC1, was identified as the enzyme expressed in gastrointestinal tissues, 
where it edits apolipoprotein B mRNA post-transcriptionally to create a premature 
stop codon22. Another example of the APOBEC protein family is activation-induced 
deaminase (AID), which is expressed in B cells and known to be essential for IgG 
class switching and somatic hypermutation23. One thing in common for those two 
early members of the APOBEC family is that they all induce the deamination of 
cytidine and result in a cytidine (C) to uridine (U) conversion. Therefore, researchers 
suspected that APOBEC3G has similar enzymatic activities, especially since 
APOBEC3G contains two cytidine deaminase domains, and that turned out to be true. 
A number of studies done by different research teams found that the expression of 
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APOBEC3G in permissive cells infected by Vif-defective virus produces 
APOBEC3G-containing viral progeny24 25 26. Those progeny, after infecting new 
cells, yield reverse transcripts that contain disproportionately large numbers of 
guanosine (G) to adenosine (A) mutations on the positive strand DNA, often affecting 
over 10 percent of all guanosines on viral cDNA. Since most mutations are G to A as 
opposed to C to T, it is believed that APOBEC3G selectively targets the transiently 
exposed single strand DNA26 (Figure 2).  
 
Two additional characteristics associated with APOBEC3G activity were soon 
described in a series of studies: 1. APOBEC3G shows a strong preference for specific 
nucleotide sequences and the most favored site is the 5’ -CCCA (the affected C 
underlined). Interestingly, a C to U conversion at this site on the negative sense DNA 
corresponds to a tryptophan (TGG) to stop codon (TAG) conversion on the mRNA, 
 
Figure 2. APOBEC3G targets transiently exposed single strand DNA. In most cases, 
C to U conversion takes place on the negative strand DNA as RNase digests away the 
initial RNA template. This will result in an overall G to A conversion of the viral 
cDNA. However, there are exceptions. During the later phases of reverse 
transcription, plus strand DNA of the U3 region of the 5’-LTR and the primer binding 
site are thought to be transiently exposed and thus could be vulnerable to APOBEC3G 
activity27. In those cases, APOBEC3G activity results in C to T mutations on cDNA.  
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and thus has a good chance of prematurely interrupting viral protein translation23 26 28; 
2. It is shown that APOBEC3G induced mutations become more likely to occur, 
going from the 5’ to 3’ direction of the positive sense DNA26 27. This polarity of 
APOBEC3G-induced mutation has been attributed to the fact that the 5’ end of the 
negative sense DNA is first reverse transcribed and thus exposed (to single-strand-
DNA-targeting APOBEC3G) for a longer period of time than the 3’ end27.  
 By inducing hypermutations on the viral genome, APOBEC3G can effectively 
inhibit HIV infection via two pathways. Harris et al. showed that cellular DNA repair 
enzymes could potentially recognize uridine residues, leading to degradation of 
mutated reverse transcripts as a result of abortive repair of unpaired DNA strands23. 
Even if the APOBEC3G edited reverse transcripts can survive the host DNA repair 
mechanism, the resulting mutation burden is often sufficient to disrupt viral genetic 
integrity and suppress viral replication22. More recently, the Malim group has shown 
that APOBEC3G may also inhibit elongation of HIV-reverse transcripts via a 
hypermutation-independent mechanism, although the exact mechanism remains 
unclear29. That is not to say that APOBEC3G is the only protein in the family 
involved in antiretroviral activity. In fact, it was even suggested that the major 
restrictor of HIV-1 infection in vivo might be APOBEC3F, while APOBEC3G plays a 
key supporting role29. 
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As mentioned above, APOBEC3G induces hypermutation on the  HIV viral 
genome and by doing so, effectively inhibits viral replication. Therefore, it is 
necessary for the virus to develop counter measures. We have learned that Vif can 
antagonize APOBEC3G, based on previous experimental results that Vif can reverse 
the non-permissive phenotype conferred by APOBEC3G in a permissive cell line; 
however, Vif does not have any enzymatic activity and it is unlikely that Vif alone 
can prevent integration of APOBEC3G into HIV virions. Initially it was found that 
Vif could directly bind to APOBEC3G and somehow lead to proteosome-mediated 
degradation of APOBEC3G 31  32  33 . A detailed molecular mechanism was 
subsequently worked out by the Yu group in the same year 34 . Through 
immunoprecipitation assays followed by mass spectrometry, Vif was shown to recruit 
the cellular proteins cullin-5 (Cul5), elongin B, elongin C and Rbx1 to form a 
 
Figure 3. Vif binds APOBEC3G and forms an ubiquitin-ligase complex by recruiting 
elongin B (B in the figure), elongin C (C in the figure), Cul5 and RBX1. The next 
step is Cul5-RBX1-dependent ligation of ubiquitin to APOBEC3G by E2 enzyme. 
The E2-ubiquitin conjugating enzyme receives its ubiquitin from an E1 enzyme. 
Once APOBEC3G is tagged with poly-ubiquitin tail, it will be destined for 
proteasomal degradation. Adapted from Harris and Liddament. Nat. Rev. Immunol. 
200430.   
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ubiquitin-ligase complex. The complex allows Vif to bind APOBEC3G and induce 
ubiquitination and degradation of APOBEC3G (Figure 3). Similar results were later 
replicated by Kobayashi et al. in 200535. Over the next several years, a number of 
studies were published that employed mutation analysis to map out the interaction 
domains among components of the Vif complex and APOBEC3G36 37 38 39 40 41. 
However, all attempts to obtain crystal structure data had not been successful. In 
2011, two groups identified a cellular protein cofactor required for Vif function—
CBFβ42 43, which eventually led to the successful crystallization of Vif-Cul5-CBFβ-
ElonginB-ElonginC44 (Figure 4). The structural data, albeit lacking APOBEC3G, 
provides a structural basis for how Vif antagonizes APOBEC3G and offers many 
insights for future drug design.  
 
Figure 4. Overall structure of Vif-CBF-β-CUL5-ELOB-ELOC based on 
crystallography data. Vif interacts directly with ElonginB, Cul5 and CBFβ, offering 
multiple potential targets for antiviral drug design. Adapted from Guo et al. Nature. 
2014.  
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 In summary, APOBEC3G and Vif is the first discovered and best-studied pair 
of restriction factor and the associated viral evasion mechanism. APOBEC3G can 
suppress HIV replication in the absence of Vif by inducing hypermutation during 
reverse transcription, while HIV-1 Vif can counteract by inducing proteasomal 
degradation of APOBEC3G. There seems to a balance between the Vif activity and 
APOBEC proteins. Mutations may not be particularly bad for the virus at a sub-lethal 
level. After all, the pathogenicity of HIV-1 depends on its error-prone reverse 
transcriptase. Studies have shown that, during the course of a HIV infection, Vif does 
not antagonize APOBEC3 activity completely13 25 26 and may even utilize the 
mutation-inducing power of APOBEC3 to generate more genetic diversity to 
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IV. TRIM5α 
 In 2004, TRIM5α was identified as a result of large-scale screen of rhesus 
macaque genes that could restrict HIV-1 replication when expressed in human cells15. 
Unlike APOBEC3G, tetherin and SAMHD1, TRIM5α is not known to be actively 
targeted by any viral accessory proteins. TRIM5α is 56kDa cytoplasmic protein that 
belongs to the family of TRIM proteins. All TRIM proteins are characterized by their 
tripartite motif (TRIM), which consists of RING, B-Box type 2 and coiled coil 
domains45. TRIM5α, in addition to the TRIM domain, possesses a C-terminal B30.2 
or PRYSPRY domain46. Additionally, TRIM5α is ubiquitously expressed throughout 
the human body, including in T cells47. The expression level is generally low but can 
be upregulated by IFN48. Another unique feature that distinguishes TRIM5α from 
other restriction factors is that in general, endogenous TRIM5α proteins are poor 
inhibitors of retroviruses that are found in the same host species but can inhibit 
retroviruses infecting other species. For example, while TRIM5α from Rhesus 
macaques (rhTRIM5α) is a strong inhibitor of HIV-1, it does not restrict replication of 
the SIV strain commonly infecting Rhesus macaques, SIVmac15. Likewise, human 
TRIM5α (hTRIM5α) is a strong inhibitor of N-tropic murine leukemia virus (N-
MLV) and equine infectious anemia virus (EIAV) but is essentially inactive against 
HIV-149 50. It is also reported that TRIM5α can provide mild restriction of HIV-2, 
which may account for why HIV-2 is more difficult to transmit and less progressive 
than HIV-151. 
TRIM5α is believed to act following the entry of the retroviral nucleocapsid 
into the cytoplasm of host cells and is responsible for the failure of viral cDNA 
synthesis15. The exact mechanism is not as well characterized as the other restriction 
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factors possibly due to the limitation of biochemical and biophysical techniques10. It 
is, nonetheless, clear that TRIM5α can bind directly to the HIV-1 capsid via its 
PRYSPRY domain52. Because previous study has shown that interaction between 
TRIM5α and capsid (CA) monomers is weak53, the researchers soon recognized the 
importance of the coiled coil domain, because it drives the formation of TRIM5α 
dimers45. TRIM5α can then continue on to form hexamers from dimers, a process 
enhanced in the presence of incoming viral capsid and may involve the B-Box type 2 
domain54, and the high-avidity binding to CA conferred by the hexamers was later 
shown to be essential for efficient restriction55. However, aside from the binding of 
the TRIM5α multimer to capsid in a polyvalent manner, no other activities associated 
with TRIM5α have been shown to be absolutely necessary for its restriction effect on 
HIV. The current consensus among the scientific community is that TRIM5α may be 
capable of suppressing viral replication via at least two pathways10, a redundancy that 
is commonly encountered among pathways of human innate immunity (Figure 5). The 
RING domain of TRIM5α proteins possesses E3 ubiquitin-ligase activity and 
therefore, the initial postulate was that by binding to CA in the cytoplasm, TRIM5α 
could lead to accelerated and disrupted uncoating of the virus48 51 56. Experimental 
results further suggested that TRIM5α’s RING and B-Box type 2 domains allow the 
TRIM5α-virus complex to autoubiquitinate and undergo proteasomal degradation57.  
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Figure 5. Two pathways that may be responsible for TRIM5α’s restriction activity 
upon binding to viral capsid, one proteasome-dependent and the other proteasome-
independent. Refer to the text for further details. Adapted from Malim and Bieniasz. 
Cold Spring Harb. Perspect. Med. 2012. 
  
Because the reverse transcription has to take place in the capsid environment, pre-
mature capsid fragmentation induced by TRIM5α will presumably lead to early 
termination of the viral life cycle. However, it wasn’t long before researchers realized 
that TRIM5α could even suppress HIV-1 replication in the presence of proteasome 
inhibitors or in cell lines deprived of active ubiquitin activating E1 enzymes58. 
Inhibiting proteasome activity can protect viral the nucleocapsid from premature 
disassembly and restore viral reverse transcript level, yet cannot reinstitute 
infectivity59. In addition to directly inhibit HIV-1 replication in cells, TRIM5α may 
also be involved in the activation of NFκB signaling and innate immune responses60; 
however, more research remains to be done in that area.  
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That a particular TRIM5α can selectively inhibit certain retroviruses but not 
others is most likely the result of virus-host co-evolution. Presumably, the host-
specific TRIM5α is a hurdle that a retrovirus has to overcome when crossing host 
species barriers. Most species-specific differences in TRIM5α’s restrictive 
capabilities are attributable to the CA sequence variation among retroviruses and host-
specific TRIM5α’s ability to recognize those sequences, predominantly in the 
PRYSPRY domain. Researchers have shown that either substitution of hTRIM5α 
PRYSPRY with rhTRIM5α sequence or a single amino acid change at the 322 
position of hTRIM5α is sufficient to activate restriction of HIV-161 62. There are even 
TRIM5α polymorphisms within species. Preliminary studies on human TRIM5α 
polymorphisms have shown reduced HIV-1 infection susceptibility among individuals 
with high TRIM5α levels63 and accelerated disease progression among individuals 
with the homozygous 43Y TRIM5α  genotype compared to 43H heterozygotes and 
homozygotes64. It is, however, unclear if TRIM5α will become an ideal candidate for 
HIV prophylaxis. Although HIV-1 lacks an accessory protein that is able to 
counteract the restrictive effects of TRIM5α, it is obvious that potential mutations on 
CA may quickly render TRIM5α ineffective since a similar mutation event must have 
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V. Tetherin and Vpu 
The third addition to the restriction factor family is tetherin. Initially, studies 
indicated that the Vpu accessory protein was required for virion release from some 
cell lines but not the others65, and the absence of Vpu rendered HIV-1 sensitive to an 
IFN-α-induced tetherining mechanism that trapped viral progeny on the surface of the 
infected cells66 67. Finally, tetherin was identified to be the protein responsible for this 
previously described tethering mechanism14 68.  
 
Figure 6. A structural basis for the anti-viral effect of restriction factor tetherin. 
Tetherin dimer is able to trap enveloped nascent virion at the cell surface during 
release by infiltrating a pair of membrane anchors into the viral envelope, while 
retaining the other pair in the infected cell membrane. C represents C-terminal of the 
protein, while N, the N-terminal. Adapt from Venkatesh and Bieniasz. PLoS Pathog. 
2013.  
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Tetherin is a type II single-pass transmembrane protein, containing a short 
cytoplasmic tail followed by a N-terminal transmembrane domain, a C-terminal 
Glycosyl-phosphatidylinositol (GPI) anchor, and a ~110 amino acid ectodomain (ED) 
in between69. The extracellular part alone forms a single long α -helix and interacts 
with a second tetherin molecule to adopt a canonical coiled-coil configuration70. 
Three disulfide bonds are formed between two tetherin molecules at C53, C63, and 
C91 position69.  
The exact antiviral mechanism of tetherin is rather unspecific, given that 
tetherin is active against members from at least four virus families: retroviruses, 
filoviruses, arenaviruses and Herpesviruses71, and some viruses have even evolved a 
counteractive mechanism72. But essentially in all cases, tetherin is a damage control 
mechanism for the host, terminating viral spread as a last-line of defense. Based on 
the protein structure of tetherin69 73, its anti-viral function is fairly self-explanatory. 
The tetherin dimer has two potential membrane-associated domains at both ends (one 
transmembrane domain and one GPI anchor) and, by attaching one end to the infected 
cell and the other end to the enveloped virion, tetherin prevents nascent virions from 
being released. Although it was shown that two tetherin ED could associate into a 
tetramer by forming an anti-parallel four-helix bundle at their N terminus in vitro, the 
tetrameric structure is not necessary for tetherin’s antiviral activity69 74. Most recently, 
it was shown that tetherin adopts an “axial” configuration in its functional state 
(Figure 6) with one pair of membrane domains in infected cell plasma membrane and 
the other pair in viral envelope69. While either end of the tetherin dimer can be 
inserted into a virion (N-terminal transmembrane domain or GPI anchor), Venkatsh 
and Bieniasz observed a preference for the insertion of tetherin’s C-terminal GPI 
anchor into the virion envelope, possibly because this position offers some advantages 
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for host cell signaling since the N-terminal cytoplasmic tail remains inside the host 
cell69.   
Given the promiscuous nature of the anti-viral activity exerted by tetherin, it is 
foreseeable that as long as the overall protein structure remains intact, the specific 
amino acid sequence does not matter much. In fact, a completely artificial tetherin-
like protein, assembled from structurally similar but unrelated protein domains, can 
mimic tetherin’s activity10. Likewise, because tetherin does not target a specific viral 
protein but rather interacts with the largely host-derived viral envelope, it would seem 
impossible for the virus to evade by avoiding interaction. The viruses have to come up 
with a way to avoid the localization of tetherin to the plasma membrane altogether. 
HIV’s solution is its accessory protein Vpu (Figure 7).  
 
Vpu is a ~14 kDa protein consisting of a single transmembrane helix and a 
small cytoplasmic domain10. Early studies have shown that Vpu and tetherin can be 
 
Figure 7. A working model portraying multiple mechanisms of Vpu-mediated down-
regulation of cell surface tetherin level. SCFβ-TrCP (shown in red) is a E3 ubiquitin 
ligase. Adapted from Dube et al. Retrovirology. 2010.  
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co-immunoprecipitated and give positive results in bimolecular fluorescence 
complementation assays.  Additionally, the presence of Vpu reduces tetherin level at 
cell surface67 75 76. Most recently, McNatt et al. were able to demonstrate the direct 
interaction of Vpu and Tetherin in the cell membranes via their transmembrane 
domains77. Although an accurate molecular mechanism of Vpu as an antagonist is still 
lacking, it is highly possible that Vpu employs multiple mechanisms. It has been 
shown that Vpu may directly induce proteasomal degradation of tetherin by recruiting 
host proteins to form an SKP1-Cullin1-βTRCP ubiquitin ligase78 79.  Alternatively, 
Vpu might induce sequestration of tetherin in the trans golgi network, which may 
later undergo lysosome-mediated degradation. Vpu might also saturate tetherin GPI 
anchors at the viral assembly site76 80.   
Finally, it may be interesting to mention that most SIV do not encode Vpu 
protein at all81 and have developed a different tetherin evasion mechanism involving 
the Nef protein 82. In some cases, primate lentiviruses may even utilize the Env 
protein as a tetherin antagonist83. These findings may have significant implications 
when considering both the origin of HIV and the design of future HIV drugs targeting 
Vpu. 
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VI. SAMHD1 and Vpx 
 The first important clue that preceded SAMHD1 discovery was an observation 
made on HIV-1 viral tropism. It has been long established that HIV-1 failed to infect 
a number of immune cell types that possess the necessary cell receptor and co-
receptors for HIV-1, namely dendritic cells84, macrophages85 and resting CD4+ T 
cells86 87. This inability to infect certain immune cells was suspected to be attributable 
to the absence of the genomic Vpx protein in HIV-1, because HIV-2 and SIVmac, 
both encoding the accessory protein Vpx, could effectively infect those cells but 
failed to do so with a defective Vpx88 89. Furthermore, HIV-1 infection in monocyte-
derived macrophages (MDM) can be achieved by pre-loading the macrophage with 
Vpx via a virus-like particle (VLPs) delivery system82 83. The specific molecular 
mechanism underlying this function of Vpx was also defined when researchers 
demonstrated that Vpx activity is dependent on a functional proteasome82. It was 
determined that Vpx recruits cellular proteins to form an E3 ubiquitin ligase complex 
CRL4DCAF1, consisting of DCAF1, DDB1 (damage-specific DNA binding protein1), 
Cullin4 (Cul4) and Rbx190 91 92.  
 The only missing piece of this puzzle was the host protein Vpx targets and this 
piece finally came in 201116 18. Hrecka et al. used a proteomic screening approach 
looking for a cellular protein that is associated with the CRL4DCAF1 ubiquitin ligase 
only in the presence of Vpx16. In contrast, Laguette et al. took a somewhat similar but 
more direct approach. They directly pulled down Vpx from a monocyte cell line 
stably expressing Vpx and subjected the pull-down eluates to SDS-PAGE and mass 
spectrometry18. In both cases, SAMHD1 was identified and both groups further 
showed that knocking out SAMHD1 enhances HIV-1 infectivity and renders it Vpx 
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independent16 18. Later in the year, an elegant study from Berger et al. nicely 
complemented the results from Hrecka et al. and Laguette et al. by demonstrating 
CD14 positive monocytes isolated from individuals with Aicardi-Goutières Syndrome 
(AGS), who are known to have no endogenous SAMHD1 expression, are highly 
susceptible to HIV-1 infection93.  
 
Figure 8. a. Upon infecting dendritic cells (the same mechanism applies to 
macrophages), HIV-2 and SIVsm deliver their Vpx protein into the cell cytoplasm, 
where it then binds to SAMHD1. Vpx recruits Cul4-DDB1-DCAF1 to form an E3 
ubiquitin ligase, leading to proteasomal degradation of SAMHD1. In contrast, HIV-1 
does not encode Vpx and SAMHD1 thus can inhibit HIV-1 replciation by 
mechanism(s) that remains unclear. Adapted from Lim & Emerman. Nature. 201194.  
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 SAMHD1 is expressed at basal levels in most tissues95 but is highly expressed 
in dendritic cells and other cells of the myeloid lineage18. Similar to many other 
restriction factors, SAMHD1 too is upregulated following type I IFN treatment91. The 
mechanisms of SAMHD1’s anti-HIV-1 activity are still intensively studied today. The 
main enzymatic activity described to date is SAMHD1’s dGTP-dependent dNTPase 
activity, which allows it to deprive the cellular dNTPs pool available for viral 
replication 96  97  98  (Figure 8). SAMHD1 converts dNTPs to the constituent 
deoxynucleoside and inorganic triphosphate, and data derived from crystallography 
suggested a tetrameric configuration is needed for full enzymatic activity93 95.  
However, dNTPase activity is unlikely the only function of SAMHD1 as a 
restriction factor. Recent studies have shown that SAMHD1 is regulated by 
phosphorylation99 100 101. A phosphorylation event that takes place at a theronine 
residue near the C-terminal of SAMHD1 (C592) was shown to inhibit SAMHD1’s 
restriction activity, while maintaining the dNTPase activity. Moreover, it was even 
demonstrated that SAMHD1 possesses exonuclease activity102. It is thus obvious that 
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VII. Others  
 As mentioned earlier, rigorous investigations have revealed over 30 host-
restriction factors associated with anti-HIV activities since the initial discovery of 
APOBEC3G. It is likely that those may only be the tip of the iceberg considering the 
complexity of the human innate immune system. Other than APOBEC3G and other 
proteins in the APOBEC3 family, TRIM5α and other proteins in the TRIM family, 
tetherin (BST-2) and SAMHD1, which are relatively well studied, a variety of other 
host proteins were identified in recent years to suppress HIV-1 replication in a cell-
autonomous manner, many of which are IFN-inducible and non-HIV-1 specific. In 
this section, I will list three examples: Schlafen 11, TREX1 and MxB.  
 In a study published in Nature in 2012, a group of researchers from the 
University of California at San Diego described the anti-viral mechanism of a cellular 
Type I IFN-inducible protein Schlafen 11 (SLFN11)103. SLFN11 belongs to a large 
family of proteins initially described in 1998104 that are preferentially expressed in 
lymphoid tissues. I It was shown that a cell line expressing SLFN11 produces fewer 
virions than a cell line that does not express SLFN11, even though the viral life cycle 
up to the stage of integration of viral DNA into the host genome remains 
unaffected101. Based on the fact that SLFN11 binds to all tRNAs in vitro and on a 
previously unexplained observation made by Coccia et al. that viral protein synthesis 
was inhibited in HIV-infected cells following IFN treatment105, the authors proposed 
that SLFN11 can interfere with viral protein synthesis to achieve viral replication 
inhibition, specifically by depleting certain rare tRNAs. Viruses that have rare a 
codon bias (an HIV genome that is particularly A-T rich) may be especially 
vulnerable to this inhibition101.  
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 Strictly speaking, TREX1 is not a restriction factor, but rather a pro-virus host 
factor. However, it is believed to be important for HIV-replication by inhibiting 
innate immune responses to HIV cDNA106. TREX1 is a 3’ exonuclease that contains 
three well-conserved exonuclease motifs at its N-terminus and a hydrophobic region 
at the C-terminus that is responsible for TREX1’s localization to the cytoplasm and 
endoplasmic reticulum. TREX1 binds to and digests excessive cytosolic HIV DNA so 
that viral DNA will not activate IFN expression via a pathway involving TBK1, 
STING and IRF3. In contrast, in cells derived from TREX1 knockout mouse and 
human CD4+ T cells and macrophages in which RNAi inhibited TREX1 expression, 
cytosolic HIV DNA accumulated and HIV infection induced type I IFN production.  
 Human dynamin-like myxovirus resistance 2 (Mx2 or MxB) is the most 
recently added member to the repertoire of restriction factors. Late in 2013, three 
groups reported a cell-autonomous anti-HIV-1 restriction factor, previously known as 
MxB17 107 108. Although the protein was first identified in the 1980s109, it was not 
associated with any anti-viral activity then and was therefore quickly overshadowed 
by the other protein in the family—MxA, which has long been recognized as a 
broadly acting inhibitor of many viruses, including influenza A virus110. Although the 
anti-HIV mechanism of MxB is currently under investigation, it was shown that MxB 
blocks the HIV-1 life cycle at a late post-entry step, inhibiting both nuclear cDNA 
accumulation and integration17 105 106. Additionally, the researchers isolated an escape 
HIV17 111 112strain from serial passage of HIV-1 through an MxB-expressing cell line 
and found a single mutation on the viral CA protein. Because the A88 residue is 
known to be indispensable for interacting with a host protein peptdyl-prolyl-
isomerase cyclophilin A (CypA), the authors suspected that CypA and CA are 
involved in the anti-viral activity of MxB, which might be a reasonable guess since 
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previous studies on MxA114, which is structurally superimposable on MxB, have 
shown that MxA can oligomerize and interact with the nucleocapsid of many 
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VIII. Implications of HIV Viral-Host Interactions 
 The repeated failure to produce an effective HIV vaccine is a humbling 
reminder that a full understanding of the immune response to HIV is still lacking116. 
Understanding how a virus with extremely limited coding capacity can evolve in a 
way that enables it to circumvent and bypass our powerful and intricate immune 
system is not only a biologically interesting but also a medically significant question. 
The identification of host restriction factors and corresponding viral evasion 
mechanism may merely be the first step, allowing us to know what we are dealing 
with (Figure 9). After all, a natural retroviral infection does not set off the production 
of cytokines or IFNs, whereas most restriction factors are IFN-inducible. Although 
the history of restriction factors is short, the scientific community has already been 
able to transform some of our knowledge on restriction factors and viral antagonists to 
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For instance, our knowledge on host restriction factors and their corresponding 
antagonists have played an important role in allowing us to trace back the 
evolutionary history of SIV because lentiviral interspecies transmission are partly 
driven by the evolution and capacity of viral accessory genes, including vpx, vpr, vpu, 
and vif, to antagonize host antiviral factors, such as APOBEC3, SAMDH1 and 
tetherin. We now know that HIV-1 resulted from cross-species transmission of 
SIVcpz, a simian immunodeficiency virus that naturally infects chimpanzees. SIVcpz 
itself is the result of an earlier recombination event between two SIV stains from Old 
World monkeys. The passage to chimpanzees may have served as an intermediate 
step for SIV that facilitates its adaptation to humans117 118.  
 
Figure 9. An illustration of the HIV-1 life cycle targeted by different host 
restriction factors. The virus has also developed mechanisms to evade restriction 
factors in order to produce progeny. Studying this dynamic HIV-1-host interaction 
may provide insights for future antiretroviral treatment design and also shed light on 
the origin of HIV virus. Adapted from Haller. Cell Host Microbe. 2013.  
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Although deciphering the evolution of the SIV-HIV transition may help 
explain why the virus produces such different disease progression patterns in primates 
and human respectively, the most tangible benefits from studying HIV-host 
interactions at the basic science level is the potential to apply that knowledge 
clinically. Currently, clinical applications can be divided into two conceptually 
promising areas: 1. Drug design that disrupts viral protein antagonism or mimics host 
restriction factors still capable of resisting viral infection; 2. Population level studies 
that aim at associating long-term non-progressors (LTNPs) or elite controllers (ECs), 
individuals who are able to maintain low plasma viremia and high CD4+ cell count 
without antiretroviral treatment (ARV) for a relatively long time, to certain restriction 
factor polymorphisms119.  
 APOBEC3G was the first discovered restriction factor and therefore we now 
have the most knowledge about it, as well as other APOBEC3 family proteins. 
Population-based studies have been published to examine if APOBEC3G or 
APOBEC3G contribute to LTNPs’ ability to control viral replication118. The results 
are ambiguous and inconsistent, possibly due to the generally small sample size and 
the fact that the ability to achieve long-term control of HIV viremia is likely multi-
factorial. It might also be possible that A3G’s hypermutation-independent antiviral 
activity was not accounted for, for most studies measured the hypermutation level as 
the readout for APOBEC3G activity level 120 . Nevertheless, an APOBEC3G 
polymorphism identified (rs8177832) in African-Americans and the 6892C allele 
present in European-American populations were associated with accelerated disease 
progression121 122 123. A recent study that examined 19 ARV-naïve individuals (12 
LTNPs and 7 not) showed that the deaminase-dependent antiviral activity might only 
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contribute to viral replication control above a threshold level while the deaminase-
independent activity does not require a threshold level124.  
 Scientists have also made progress on exploiting the APOBEC3 family 
proteins for development of new treatments. However, any strategies involving 
upregulating APOBEC3 level needs to be approached cautiously—in host cells, 
APOBEC protein expression and activity must be strictly regulated in order not to 
backfire on the host genome.  Previous studies have shown that over-expression 
causes genome damage and leads to cancer125. Regardless of the side effects, 
APOBEC3G expression enhancement can be achieved by stimulating CCR5 and 
CD40 with CCL3 and CD40L chemokines, respectively, as well as with heat shock 
protein 70 (HSP70), which is present in HIV virions126 and was previously shown to 
bind directly to CCR5127. One study has successfully demonstrated the use of HSP70 
as a preventive method in rhesus macaques128. In addition, the Vif-APOBEC3G, Vif-
Cul5, Vif-CBFβ interfaces are also promising sites for the development of new 
antiretroviral drugs, such as RN-18129, which targets the Vif protein directly. With the 
recent addition of APOBEC3G130 131 and Vif-Cul5-ElogBC-CBFβ43 complex high-
resolution structural data, new ARVs should be in the pipeline soon. Alternatively, 
there have also been attempts to enhance incorporation of APOBEC3G into nascent 
virions by deploying a APOBEC3G-viral (for example, Vpr and Nef) protein fusion 
delivery system132 133.      
 TRIM5α is another candidate under rigorous investigation, mainly as a gene 
therapy option, since there is no known viral antagonist. At the population level, 
several SNPs of huTRIM5α were identified, but only two were studied for their effect 
on disease progression134 135. It was suspected that the TRIM5α H43Y polymorphism 
occurs at the RING domain of TRIM5α and may affect its E3 ubiquitin ligase activity, 
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but it could not be fully confirmed in in vitro assays132. The other polymorphism, 
R136Q, occurs at the domain involved in TRIM5α oligomerization and thus 
potentially may influence its antiviral activity. However, epidemiological studies gave 
inconsistent results63 136 . TRIM5α gene therapy research, however, is rather 
productive. Since huTRIM5α does not itself target HIV-1, researchers have tried 
engineering chimeric TRIM5α using the PRYSPRY domain from the rhesus 
macaque137 and chimeric TRIM5αCyp combining huTRIM5α and huCypA138 (a idea 
inspired by TRIM5Cyp from new world owl monkey), were both quite successful in 
animal models. Additionally, the recent discovery that a single nucleotide mutation of 
huTRIM5α can prevent HIV-1 evasion may allow development of gene therapy with 
no immunogenicity problems60 61. Meanwhile, because the crystal structure of the 
rhesus macaque TRIM5α PRYSPRY domain (where it interacts with CA) was already 
available139, there may be space for drug development targeting the viral CA protein.   
 Both tetherin and SAMHD1 have been discovered fairly recently, therefore, 
few clinical studies have been done on either of them. Since both restriction factors 
are IFN-inducible, an obvious way to exploit their antiviral effects is immunotherapy 
(IFN treatment). However, it turned out that not only is IFN-α treatment accompanied 
by some side effects, it is also associated with increased risk of progression to 
AIDS140. An alternative approach is to design molecules to prevent vpu binding to 
tetherin at the transmembrane domain141. In the case of SAMHD1, clinical studies are 
still lacking but potential drug development can target the SAMHD1-Vpx interface, 
again with the help of available biophysical data, or inhibit phosphorylation 
(deactivation) of SAMHD1. Other than the four well-studied restriction factors, 
polymorphisms in TREX1, specifically the single nucleotide polymorphism 
rs3135945 was significantly associated with HIV infection142. A recent study looking 
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at the host restriction factor expression profile among HIV-1 elite controllers in a 
UCSF cohort has successfully identified schlafen 11 as a potential signature of HIV-1 
elite controllers. The mRNA and protein expression of schlafen 11 were elevated 
among elite controllers who tend to have a low cellular activation level and low 
restriction factor levels.  
Finally, because almost all known viral evasion mechanism involves ubiquitin 
mediated proteasomal degradation, a drug that can potentially target HIV-infected 
cells and inhibit proteasome activity could be an ideal ARV candidate because it will 
be able to target multiple stages of the viral life cycle, serving the same purpose as 
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IX. Conclusion 
 Since the discovery of APOBEC3G in 2002, our knowledge on HIV-1 viral-
host interaction has expanded exponentially. A group of proteins termed restriction 
factors were found to inhibit the replication of virus in host cells. Unlike the classical 
innate immunity, which is mediated by special cell types such as Natural Killer cells, 
Dendritic cells and polymorphonuclear leukocytes (PMNs), restriction factors are 
germline-encoded and IFN-inducible proteins that provide intrinsic immunity against 
viral replication in individual host cells. Many restriction factors target specific virus 
or viruses in certain family, such as TRIM5α, while others possess rather unspecific 
antiviral mechanisms, such as tetherin. Despite of restriction factors’ potent antiviral 
activity, viruses have evolved ways to get around the host defense. Most well-studied 
restriction factors are associated with viral antagonists. Some of the examples 
mentioned in this article include Vif and APOBEC3, SAMHD1 and Vpx, tetherin and 
Vpu. The widespread of HIV-1 virus is certainly a clear indication of the equally 
strong potency of viral antagonists. The very existence of host restriction factors and 
viral antagonist clearly points to “an evolutionary ‘arm race’ that drives continuous 
rounds of selection for beneficial mutations in the genes encoding restriction factors 
and their viral antagonists, through evolutionary pressure for both host survival and 
virus replication”143.   
 In the context of HIV, which has only circulated in human host for 50 years, 
the question thus becomes why do those restriction factors exist in the first place 
before HIV has come alone and whether human can keep up with the HIV virus in 
this evolutionary arm race.  
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 To answer the first question, we need to first understand that virus in general 
has been a significant presence throughout the vertebrate evolution and this arm race 
between the virus and the host is an ancient concept144. In fact, it has been shown that 
many human restriction factors have been evolving under episodic positive selection 
throughout primate evolution141. Thus the existence of many restriction factors may 
be the result of co-evolution of human and many other ancient viruses, some of which 
may have successfully achieve co-existence with its host by incorporating their 
genetic material into host genome. The co-evolution of host and virus is a classical 
example of the “Red Queen” Hypothesis145, in which two conflicting entities undergo 
continuous adaptation to maintain the status quo. At the end of the “Red Queen” 
competition, often a balance is reached when the virus becomes avirulent enough that 
it does not cause any significant morbidity or mortality in host while remaining the 
capability of reproducing its genetic material. This long-term balance is obviously not 
reached for human and HIV. The majority of the human host has only been exposed 
to the virus for three decades and thus it is unlikely that the restriction factors can 
evolve within such a short time period. Although some of the restriction factors can 
inhibit HIV replication, it is likely they evolved to restrict replication of some ancient 
viruses (possibly retrovirus) but possess cross-reactivity to HIV.   
 Another possibility is that some of the restriction factors were involved in 
other cellular pathways before the HIV virus comes along and happens to inhibit viral 
replication. A great example is SAMHD1, which functions as not only a restriction 
factor but also an innate immune response mediator to non-viral events. Genetic 
mutations in SAMHD1 are associated with autoimmunity in humans called Aicardi-
Goutières Syndrome146, potentially because SAMHD1 can prevent the accumulation 
of inappropriate retrotransposons by-products, such as single-stranded DNA 147 . 
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Likewise, APOBEC3G has been suggested to also play a similar role in control 
excessive endogenous retrotransposons by inducing hypermutation148. Additionally, 
restriction factors may play role in the immune signaling pathways. In many ways, 
restriction factors are similar to pattern-recognition receptors because they recognize 
certain structure pattern of the virus141. Specifically, TRIM5α, upon binding to the 
retroviral capsid, activates NF-κB signaling and a distinct innate immune response. In 
the absence of retrovirus, TRIM5α is shown to still function as a constitutive 
signaling intermediate in the NF-κB cascade60 149. Similarly, tetherin has been shown 
to activate NF-κB, in addition to its antiviral activity against enveloped virus150.  
 Clearly further research on restriction factors will help us better understand 
our innate immune system and how restriction factors talk to the other components of 
the immune system. But for now, a more urgent question would be what will be the 
outcome of this evolutionary arm race between the human host and the HIV virus. In 
the case of primates and SIV, we know they eventually co-exist. But how is it 
possible? If single nucleotide changes were the only mechanism driving the co-
evolution of human and HIV, the host would be at an enormous disadvantage since 
RNA virus mutate much faster rate than the human host, especially considering that in 
reality a host are simultaneously being challenged by a variety of pathogens. The 
answer seems to lie in the nature of genetic material utilized by virus and human. 
Because virus has a densely packed genome, it has many overlapping reading frames, 
as well as certain secondary RNA structures crucial in the viral life cycle. Due to the 
limited coding capacity, many viral proteins serve multiple functions. These factors 
severely constrain the viruses’ ability to evolve even though viral mutants are 
relatively easy to generate. In contrast, the human host has tremendous potential for 
evolution because it has two alleles for each gene. Many genes in human are also 
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duplicated, for example the APOBEC3 protein family, so that each alone can undergo 
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2012 
Research assistant 
Ashley Pearcy Ph. D. 
University of Witwatersrand 
Organization of Tropical Studies 
A preliminary assessment of the Mutale River and its 
suitability for Nile Crocodiles.  
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Master of Health Science 
Molecular Microbiology and Immunology 
Johns Hopkins Bloomberg School of Public Health, 
Baltimore, MD !
2013 
Bachelor of Arts 
Biology with honors 
Grinnell College, Grinnell, IA !
2012 
Off-campus studies 
Grinnell in Washington Semester 
Grinnell College, Washington, DC !
2012 
Summer Program 
Global Health Issues in South Africa  
Organization for Tropical Studies, Skukuza, South Africa 
Duke University, Durham, NC !
2012 
Off-campus Studies 
African Ecology and Conservation Semester 
Organization for Tropical Studies, Skukuza, South Africa  
Duke University, Durham, NC !!!!!!!!

























Environmental Health Intern 
Physicians for Social Responsibility, Washington, DC 
Performed background research, produced synthesis, 
and reported to the director on environmental health 
policies. Compiled and designed information 
pamphlets on shale gas drilling and off-shore wind 
energy campaigns. !
2012 
Intern at Doctors for America 
Center for American Progress, Washington, DC 
Conducted daily internet research on states’ stands on 
the Affordable Care Act. Maintained membership/




Tshulu Trust, Limpopo, South Africa 
Developed, initiated and improved a computer literacy 
program for community members. Designed and 
organized a system of monitoring feedback on Tshulu’s 
projects. Attended community consultation meetings 




Grinnell College, Grinnell, IA 
Served as laboratory teaching assistant for senior level 
biology course for one semester. Tutored Chinese at 
the Chinese Lab for two and a half years.  !!
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